CC BY-NC-ND 4.0 · International Journal of Practical Otolaryngology 2021; 4(01): e21-e28
DOI: 10.1055/s-0041-1723788
Original Article

A Study on 615 Cases of Idiopathic Epistaxis

Tomoko Kida
1   Department of Otolaryngology, Takarazuka City Hospital, Takarazuka, Hyogo, Japan
,
Hideki Oka
1   Department of Otolaryngology, Takarazuka City Hospital, Takarazuka, Hyogo, Japan
,
Katsuya Fushimi
1   Department of Otolaryngology, Takarazuka City Hospital, Takarazuka, Hyogo, Japan
,
Mariko Honda
1   Department of Otolaryngology, Takarazuka City Hospital, Takarazuka, Hyogo, Japan
,
Junya Fujiki
1   Department of Otolaryngology, Takarazuka City Hospital, Takarazuka, Hyogo, Japan
,
Kenzo Tsuzuki
2   Department of Otolaryngology—Head and Neck Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
› Author Affiliations

Abstract

Epistaxis is one of the most common complaints encountered in the field of otorhinolaryngology. Although hemostasis can be achieved by outpatient treatment in many cases, we have also encountered some difficult-to-treat patients who developed rebleeding or required admission and surgery. We conducted a retrospective analysis of the clinical features of 615 patients with idiopathic epistaxis who were seen at our hospital between 2012 and 2019. We analyzed the patient data and clinical factors associated with epistaxis, including the age, gender, month (season) of visit to our hospital, accompanying systemic complications, bleeding points, procedures used for treatment, history of rebleeding, and history of hospitalization. The patients with epistaxis were predominantly males in their 70s. In regard to the season of presentation, patients with epistaxis were encountered more frequently in the winter than in the summer. Most patients had initially been treated by electrocoagulation. Hypertension was the most common underlying disease. Rebleeding within 7 days after the primary treatment occurred in 11.5% (71/615) of patients. Analysis identified heart and liver disease and antithrombotic drug use as significant risk factors for rebleeding. Although in the overall subject population the bleeding point was most frequently observed in Kiesselbach plexus area, the bleeding point was observed more often in the middle nasal meatus or olfactory cleft in the patients with rebleeding. The most common indication of hospitalization was difficulty in hemostasis, and the bleeding point in most of the hospitalized cases was unknown or in the posterior nasal cavity. The analysis revealed that it may be important to attempt endoscopic hemostasis in patients in whom the bleeding point is identified in the posterior nasal cavity.



Publication History

Received: 22 May 2020

Accepted: 09 October 2020

Article published online:
02 February 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Fuji S, Hirai M, Shigehara A, Nakai K, Orita Y. Risk factors for re-bleeding after the treatment of epistaxis. Nippon Jibiinkoka Gakkai Kaiho 2016; 119 (08) 1117-1126
  • 2 Willems PWA, Farb RI, Agid R. Endovascular treatment of epistaxis. AJNR Am J Neuroradiol 2009; 30: 1637-1645
  • 3 Morgan DJ, Kellerman R. Epistaxis: evaluation and treatment. Prim Care 2014; 41 (01) 63-73
  • 4 Kilty SJ, Al-Hajry M, Al-Mutairi D. et al. Prospective clinical trial of gelatin-thrombin matrix as first line treatment of posterior epistaxis. Laryngoscope 2014; 124 (01) 38-42
  • 5 Kucik CJ, Clenney T. Management of epistaxis. Am Fam Physician 2005; 71 (02) 305-311
  • 6 Ishinaga H, Kato A, Yamada H. Clinical study of severe epistaxis treated by surgical therapy. Pract Otorhinolaryngol (Basel) 1999; 92 (04) 363-366
  • 7 Nishikawa H, Hidaka H, Kudou T, Kobayashi T. A clinical study of 203 hospitalized epistaxis patients. Jpn J Rhinol 2012; 51 (04) 481-488
  • 8 Yukitatsu Y, Tsuzuki K, Takebayashi H, Sakagami M. Clinical study of 1,515 patients presenting with epistaxis over the last 6 years. ORL J Otorhinolaryngol Relat Spec 2016; 78 (04) 232-240
  • 9 Homma Y, Hashimoto S, Ono M. et al. Clinical study of epistaxis patients. Oto-Rhino-Laryngol Tokyo 2008; 51: 442-446
  • 10 Takano S, Uchimura K, Shigi K. et al. Retrospective study of epistaxis. Pract Otol 1999; 92 (07) 721-724
  • 11 Hasegawa T, Takegoshi H, Kikuchi S, Iinuma T. A statistical analysis of epistaxis between outpatients and inpatients [in Japanese]. Nippon Jibiinkoka Gakkai Kaiho 2004; 107 (01) 18-24
  • 12 Kodama H, Shido F, Kataura A. Statistical analysis of patients with epistaxis treated at Sapporo Medical College Hospital. Oto-Rhino-Laryngol Tokyo 1987; 30: 567-574
  • 13 Masuda Y, Nakanoboh M, Matsunaga T, Tanabe T, Kitahara S. A retrospective review of hospitalized patients with epistaxis. Pract Otol 2000; 93 (08) 629-634
  • 14 Umemoto S, Tateyama K, Watanabe T, Hirano T, Suzuki M. A clinical study of 206 hospitalized patients with epistaxis. Jpn J Rhinol 2019; 58 (02) 243-249
  • 15 Nario K, Miyahara H, Sasai H. et al. A clinical study of hospitalized epistasis patients. Jpn J Rhinol 2008; 47 (01) 1-7
  • 16 Daniell HW. Estrogen prevention of recurrent epistaxis. Arch Otolaryngol Head Neck Surg 1995; 121 (03) 354
  • 17 Nunez DA, McClymont LG, Evans RA. Epistaxis: a study of the relationship with weather. Clin Otolaryngol Allied Sci 1990; 15 (01) 49-51
  • 18 Manfredini R, Gallerani M, Portaluppi F. Seasonal variation in the occurrence of epistaxis. Am J Med 2000; 108 (09) 759-760
  • 19 Minami J, Ishimitsu T, Matsuoka H. Beneficial effects of combination therapy with losartan and low-dose hydrochlorothiazide in the treatment of essential hypertension [in Japanese]. Nippon Jinzo Gakkai Shi 2005; 47 (08) 864-869
  • 20 Kamatani M, Nakamura K, Nagata T. et al. Patients visiting the emergency department while exhibiting epistasis with neurally mediated syncope. Jpn J Rhinol 2019; 58 (04) 712-718
  • 21 Iguchi Y, Yao K, Nishiyama K, Satou K. A clinical study of surgical treatments of epistaxis. Pract Otol 2003; 96 (06) 541-547
  • 22 Lubianca-Neto JF, Bredemeier M, Carvalhal EF. et al. A study of the association between epistaxis and the severity of hypertension. Am J Rhinol 1998; 12 (04) 269-272
  • 23 Vergara Hernández J, Ordóñez Ordóñez LE. Surgical versus non-surgical treatment of posterior epistaxis [in Spanish]. Acta Otorrinolaringol Esp 2006; 57 (01) 41-46
  • 24 Srinivasan V, Patel H, John DG, Worsley A. Warfarin and epistaxis: should warfarin always be discontinued?. Clin Otolaryngol Allied Sci 1997; 22 (06) 542-544
  • 25 Ota H, Takano Y, Kawasaki M. A study of 318 epistaxis cases. Pract Otol 2010; 103 (05) 427-430
  • 26 Ishida R, Yamada H, Nishii S, Tokuriki T, Ishinaga H. Epistaxis surgery. Jpn J Rhinol 2002; 41 (04) 345-348
  • 27 Uno K, Asaka D, Okano S. et al. A case of internal carotid artery rapture caused by acute invasive fungal sinusitis. Oto-Rhino-Laryngol Tokyo 2012; 55: 28-35
  • 28 Iimura J, Hatano A, Ando Y. et al. Study of hemostasis procedures for posterior epistaxis. Auris Nasus Larynx 2016; 43 (03) 298-303
  • 29 Ando Y, Iimura J, Arai S. et al. Risk factors for recurrent epistaxis: importance of initial treatment. Auris Nasus Larynx 2014; 41 (01) 41-45
  • 30 Umapathy N, Quadri A, Skinner DW. Persistent epistaxis: what is the best practice?. Rhinology 2005; 43 (04) 305-308
  • 31 Bent III JP, Wood BP. Complications resulting from treatment of severe posterior epistaxis. J Laryngol Otol 1999; 113 (03) 252-254